Sangamo Therapeutics’ (SGMO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on Sangamo Therapeutics in a research note on Saturday, July 20th. They set a sell rating for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of Hold and an average price target of $5.67.

Sangamo Therapeutics Trading Up 28.7 %

Shares of NASDAQ:SGMO opened at $0.86 on Wednesday. Sangamo Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.48. The stock has a 50-day simple moving average of $0.49 and a 200-day simple moving average of $0.61.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. During the same period in the prior year, the company posted $0.12 earnings per share. On average, equities analysts predict that Sangamo Therapeutics will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp grew its holdings in Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 31,003 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the period. Golden State Equity Partners raised its position in Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics in the 1st quarter valued at $331,000. Finally, Assenagon Asset Management S.A. raised its position in Sangamo Therapeutics by 14.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.